NovaBridge Biosciences (NBP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NovaBridge Biosciences (NBP) has a cash flow conversion efficiency ratio of 0.007x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($13.15 Million) by net assets ($1.84 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NovaBridge Biosciences stock valuation for the company's overall valuation and market capitalisation.
NovaBridge Biosciences - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how NovaBridge Biosciences's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NovaBridge Biosciences Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NovaBridge Biosciences ranked by their cash flow conversion efficiency. Explore NBP operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Southern Cross Media Group Ltd
AU:SXL
|
0.062x |
|
TMC Life Sciences Bhd
KLSE:0101
|
0.010x |
|
Topco Technologies
TWO:3388
|
-0.003x |
|
ANGI Homeservices Inc
NASDAQ:ANGI
|
0.040x |
|
Tatung System Technologies
TWO:8099
|
-0.035x |
|
Lindsay Australia Ltd
AU:LAU
|
0.282x |
|
Hoegh LNG Partners LP
OL:HLNG
|
0.109x |
|
Vietnam Container Shipping JSC
VN:VSC
|
-0.101x |
Annual Cash Flow Conversion Efficiency for NovaBridge Biosciences (2017–2024)
The table below shows the annual cash flow conversion efficiency of NovaBridge Biosciences from 2017 to 2024. View NovaBridge Biosciences (NBP) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $201.16 Million | $-52.65 Million | -0.262x | -517.28% |
| 2023-12-31 | $1.72 Billion | $-72.85 Million | -0.042x | +88.43% |
| 2022-12-31 | $3.01 Billion | $-1.10 Billion | -0.367x | -72.83% |
| 2021-12-31 | $4.59 Billion | $-973.09 Million | -0.212x | -375.29% |
| 2020-12-31 | $5.63 Billion | $433.56 Million | 0.077x | -81.94% |
| 2019-12-31 | $-2.03 Billion | $-867.98 Million | 0.427x | +45.15% |
| 2018-12-31 | $-955.10 Million | $-280.70 Million | 0.294x | -65.06% |
| 2017-12-31 | $-299.80 Million | $-252.16 Million | 0.841x | -- |
About NovaBridge Biosciences
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial fo… Read more